EBS Q2 2020 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q2 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$395M+62.3% YoY

Gross Profit

$217M55.0% margin

Operating Income

$126M31.9% margin

Net Income

$93M23.5% margin

EPS (Diluted)

$1.73

QoQ Revenue Growth

+105.0%

Cash Flow

Operating Cash Flow

$128M

Free Cash Flow

$93M

Stock-Based Comp.

$24M

Balance Sheet

Total Assets

$2.5B

Total Liabilities

$1.3B

Stockholders' Equity

$1.2B

Cash & Equivalents

$269M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$395M	$243M	+62.3%
Gross Profit	$217M	$79M	+176.4%
Operating Income	$126M	-$7M	+1900.0%
Net Income	$93M	-$10M	+1075.8%

Revenue Segments

Product

$299M76%

Contract Development And Manufacturing

$73M18%

Contracts and Grants

$24M6%

Geographic Segments

UNITED STATES

$290M73%

Non-US

$105M27%